7月15日，康诺亚-B盘中上涨5.08%，报85.1港元，成交额6893.28万港元。
消息面上，7月9日发布的《国家基本药物目录（2026年版）》首次批量纳入创新药，康诺亚核心产品司普奇拜单抗作为4款国产Ⅰ类新药之一成功入选，意味着各级公立医疗机构须优先配备使用，有望加速基层渠道放量。此外，近日华源证券、国泰海通证券、国信证券等多家机构密集发布研报，维持或首予买入评级，指出公司商业化放量与BD收益兑现共振，吉利德收购Ouro Medicines已带来2.57亿美元首付款入账，后续里程碑付款空间可观。同日生物科技板块整体走强，科伦博泰生物涨9.8%，信达生物涨5.94%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.